Literature DB >> 23840006

Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists.

Alice E Wiedeman1, Deanna M Santer, Wei Yan, Sylvia Miescher, Fabian Käsermann, Keith B Elkon.   

Abstract

OBJECTIVE: Plasmacytoid dendritic cells (PDCs) produce high concentrations of interferon-α (IFNα) following exposure to immune complexes containing nucleic acids. We previously reported that serum from healthy donors inhibits IFNα production by PDCs in response to systemic lupus erythematosus (SLE) immune complexes, and that inhibition is mediated, in part, by IgG. IgG is the major component of intravenous immunoglobulin and is well known to exert antiinflammatory properties. Although suppression of inflammation by the sialylated subfraction of IgG has been implicated in some models, the mechanism of IFNα inhibition by IgG and the importance of sialylation have not been studied.
METHODS: SLE immune complexes or synthetic Toll-like receptor (TLR) agonists were used to stimulate total or individual cell-depleted human mononuclear cell cultures in the presence or absence of IgG, Fc fragments, F(ab')2 fragments, and their sialylated or unsialylated subfractions. Cytokines were quantified by enzyme-linked immunosorbent assay.
RESULTS: We identified 2 distinct mechanisms by which IgG inhibits IFNα production. First, IgG Fc fragments inhibited SLE immune complex-stimulated IFNα production via a sialic acid-independent mechanism, by inhibiting immune complex binding to Fcγ receptor IIa on PDCs. In contrast, the F(ab')2 fragment of the sialylation-enriched fraction of IgG inhibited TLR-7 or TLR-9 agonist-induced IFNα production but did not require the sialic acid residue itself. The inhibitory activity of IgG on TLR agonist-induced IFNα required monocyte production of prostaglandin E2, a potent suppressor of IFNα production by PDCs.
CONCLUSION: IgG attenuates IFNα production by PDCs by both cell surface receptor and intracellular pathways, depending on the nature of the inducing stimulus.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23840006     DOI: 10.1002/art.38082

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Therapy. New mechanisms of IVIg.

Authors:  Emma Leah
Journal:  Nat Rev Rheumatol       Date:  2013-07-30       Impact factor: 20.543

3.  Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation.

Authors:  Mohan S Maddur; Jamma Trinath; Magalie Rabin; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Kithiganahalli N Balaji; Srini V Kaveri; Jagadeesh Bayry
Journal:  Cell Mol Immunol       Date:  2014-12-08       Impact factor: 11.530

4.  Will sialylation change intravenous immunoglobulin therapy in the future?

Authors:  F Käsermann; I K Campbell
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

5.  Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.

Authors:  I Schwab; F Nimmerjahn
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  The plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functions.

Authors:  Julien J Karrich; Loes C M Jachimowski; Christel H Uittenbogaart; Bianca Blom
Journal:  J Immunol       Date:  2014-12-15       Impact factor: 5.422

Review 7.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

8.  Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.

Authors:  Alexandre Lederle; Bin Su; Vincent Holl; Julien Penichon; Sylvie Schmidt; Thomas Decoville; Géraldine Laumond; Christiane Moog
Journal:  Sci Rep       Date:  2014-08-18       Impact factor: 4.379

9.  Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.

Authors:  Alex Pellerin; Karel Otero; Julie M Czerkowicz; Hannah M Kerns; Renée I Shapiro; Ann M Ranger; Kevin L Otipoby; Frederick R Taylor; Thomas O Cameron; Joanne L Viney; Dania Rabah
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

10.  Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes.

Authors:  Albert Bondt; Yoann Rombouts; Maurice H J Selman; Paul J Hensbergen; Karli R Reiding; Johanna M W Hazes; Radboud J E M Dolhain; Manfred Wuhrer
Journal:  Mol Cell Proteomics       Date:  2014-07-08       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.